OncLive TV

Shahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.

Pedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

Mark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

Lakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.

Warren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.

Yasir Y. Elamin, MD, discusses NRG1 fusions in solid tumors.

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

Ryan J. Sullivan, MD, discusses the examination of tebentafusp-tebn in uveal melanoma.

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Manish A Shah, MD, discusses the importance of genetic testing in gastrointestinal cancer.

Soo Park, MD, discusses the role of cemiplimab-rwlc (Libtayo) in advanced basal cell carcinoma.

Harry H. Yoon, MD, discusses updated findings from the phase 3 RATIONALE-306 trial in esophageal squamous cell carcinoma.

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Jason Luke, MD, FACP, discusses the importance of a multidisciplinary approach in basal cell carcinoma.

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of molecular testing in ovarian cancer.

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.

Zeynep Eroglu, MD, discusses the rationale for investigating patterns of outcomes in patients with metastatic melanoma harboring BRAF mutations.

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Shilpa Gupta, MD, discusses the results of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.